Ipsen Press Releases | Latest News & Updates

Topics

Period

Filter by

Reset

Showing: 1 – 5 of 250 Press Releases

Show

Sort

24 July 2026

24 July 2026

Download Ipsen provides update on Phase III BOLD trial in biliary atresia

Ipsen provides update on Phase III BOLD trial in biliary atresia

22 July 2026

22 July 2026

Download Ipsen completes acquisition of Memo Therapeutics AG, adding first-in-class asset to Ipsen's Rare Disease pipeline

Ipsen completes acquisition of Memo Therapeutics AG, adding first-in-class asset to Ipsen's Rare Disease pipeline

13 July 2026

13 July 2026

Download IQIRVO® demonstrates statistically significant improvement in ALP normalization in patients with PBC in Phase IIIb ELSPIRE study

IQIRVO® demonstrates statistically significant improvement in ALP normalization in patients with PBC in Phase IIIb ELSPIRE study

09 July 2026

09 July 2026

Download Dysport® is the first botulinum toxin to achieve positive topline Phase III results in both episodic and chronic migraine.

Dysport® is the first botulinum toxin to achieve positive topline Phase III results in both episodic and chronic migraine.

01 July 2026

01 July 2026

Download Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio

Your dedicated contacts

Media Relations

+33 1 58 33 50 00

IpsenMediaRelations@ipsen.com

Add to contacts

Stay updated

Register to receive our latest news